BOSTON (

TheStreet

) -- Adam Feuerstein's take on the biotech week that was Nov. 19, 2010:

The week's best-performing stocks in the sector:

Entremed

(ENMD)

(+41%),

IsoRay

(ISR) - Get Report

(+33%),

Exelixis

(EXEL) - Get Report

(+31%),

Apricus BioSciences

(APRI)

(+29%) and

China Shenghuo Pharmaceutical Holdings

( KUN) (+26%)

FDA advisory panel votes 13-2 to recommend the approval of

Human Genome Sciences'

( HGSI) lupus drug Benlysta. Read the

Human Genome FDA Panel Live Blog

Human Genome Hit by Benlysta Sales Worry

Takeda

rumored to be eyeing a competing takeover offer for

Genzyme

( GENZ).

RXI Pharmaceuticals

(RXII)

says still on track to sign a major RNAi drug partnership before the end of the year.

> > Bull or Bear? Vote in Our Poll

Frontpoint Partners

said to be

shuttering health care hedge funds

in wake of insider -trading allegations. (via New York Times)

The week's worst-performing stocks:

Aastrom BioSciences

(ASTM)

(-43%),

AP Pharma

(APPA)

(-28%),

Neostem

(NBX)

(-26%),

Vermillion

(VRML) - Get Report

(-20%) and

Alnylam Pharmaceuticals

(ALNY) - Get Report

(-19%)

Medicare panel endorses on-label use of

Dendreon's

(DNDN)

prostate cancer therapy Provenge.

Amgen

(AMGN) - Get Report

rumored to be considering acquisition of Swiss biotech firm Actelion.

Roche

cuts 4,800 jobs in a corporate restructuring

that also

axes the company's research efforts into RNAi drug

development. (via Pharmalot, In the Pipeline)

European regulators accept approval application for

Cell Therapeutics'

(CTIC) - Get Report

lymphoma drug Pixuvri.

Exelixis

(EXEL) - Get Report

: Interim phase II ovarian and prostate cancer data for XL184.

FDA advisory panel votes 8-7 with one abstention to recommend approval of

MELA Sciences'

(MELA)

MELAFind skin cancer detection device. Read the

MELA FDA Panel Live Blog

MELA Sciences Is Doomed

MELA Sciences: Not So Doomed

Aastrom BioSciences

(ASTM)

presents interim phase II data on limb ischemia drug.

Resverlogix

(RVX.TO)

presents phase II data on cholesterol drug.

FDA approves

Amgen's

(AMGN) - Get Report

Xgeva for prevention of bone fractures in cancer patients.

Somaxon Pharmaceuticals

( SOMX) prices 8.8 million shares at $2.95 a share.

Pfizer

(PFE) - Get Report

and

Bristol-Myers Squibb

(BMY) - Get Report

halt study of experimental blood thinner apixaban due to an increase in bleeding.

Results from late-stage study show

Merck

(MRK) - Get Report

drug boosts good cholesterol levels and cuts bad cholesterol without safety risks

. (via Bloomberg)

Healthcare CEOs Make Big Dough

(via WSJ Health Blog)

Bayer Cuts Jobs

(via InVivo Blog)

Avanir Pharmaceuticals

(AVNR)

sells 20 million shares at $4.40 a share.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here:

Adam Feuerstein

.

>To follow the writer on Twitter, go to

http://twitter.com/adamfeuerstein

.

>To submit a news tip, send an email to:

tips@thestreet.com

.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.